



MMPs and EMMPRIN/CD147 in Physiological and Pathological Processes 2.0

Guest Editor:

Dr. Eric Huet

TRePCa—Therapeutic Resistance
in Prostate Cancer, Univ Paris Est
Creteil, F-94010 Creteil, France

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editor

MMPs have been implicated in numerous physiological and pathological situations, such as neoplasia, osteogenesis, myocardial infarction, osteoarthritis, or inflammation. Wide-ranging evidence has also implicated MMP dysregulation in tumor invasion, neoangiogenesis, and metastasis. EMMPRIN, a membrane glycoprotein greatly enriched on the surface of tumor cells, has been shown to stimulate the synthesis of MMPs in stromal cells and may account for the increased MMP expression in most cancer tissues. Apart from direct cell contact, cell interactions can also be influenced by soluble factors such as cytokines, growth factors, or extracellular vesicles. Such nodes of communication between cells might lead to dysregulations of ECM remodeling in physiological and pathological processes. In this Special Issue, original and review articles on basic science and preclinical and clinical findings are warmly welcome to contribute to our understanding of MMPs and their regulations.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)